Douglas Love net worth and biography

Douglas Love Biography and Net Worth

CEO of Annexon
Mr. Love joined Annexon Biosciences as President and Chief Executive Officer in December 2014 with extensive business and legal leadership experience in biotech. He previously served as Head of Operations for Elan Pharmaceuticals. There, Mr. Love led the Tysabri® multiple sclerosis franchise, helping to propel it to nearly $2 billion in annual sales. He also led Elan’s Alzheimer’s Immunotherapy Program, which was licensed to Johnson & Johnson for $1 billion plus milestones and royalties, as well as Elan’s global Commercial, Medical Affairs and Alliance Management groups. Mr. Love is a corporate attorney by training, and prior to joining Elan, served as an associate at the law firm Orrick, Herrington & Sutcliffe, Corporate Counsel at Amgen, Inc. and as Section Corporate Counsel at Genentech Inc., where he led the BioOncology Healthcare Law Group and launched several blockbuster programs. Mr. Love holds a J.D. with great distinction from McGeorge School of Law, Sacramento, CA, and a B.S. in business administration from the University of Southern California.

What is Douglas Love's net worth?

The estimated net worth of Douglas Love is at least $647,033.24 as of April 14th, 2022. Mr. Love owns 200,942 shares of Annexon stock worth more than $647,033 as of June 7th. This net worth estimate does not reflect any other investments that Mr. Love may own. Additionally, Mr. Love receives a salary of $830,990.00 as CEO at Annexon. Learn More about Douglas Love's net worth.

How old is Douglas Love?

Mr. Love is currently 54 years old. There are 5 older executives and no younger executives at Annexon. Learn More on Douglas Love's age.

What is Douglas Love's salary?

As the CEO of Annexon, Inc., Mr. Love earns $830,990.00 per year. Learn More on Douglas Love's salary.

How do I contact Douglas Love?

The corporate mailing address for Mr. Love and other Annexon executives is , , . Annexon can also be reached via phone at 650-822-5500 and via email at [email protected]. Learn More on Douglas Love's contact information.

Has Douglas Love been buying or selling shares of Annexon?

Douglas Love has not been actively trading shares of Annexon in the last ninety days. Most recently, on Thursday, April 14th, Douglas Love bought 60,000 shares of Annexon stock. The stock was acquired at an average cost of $2.45 per share, with a total value of $147,000.00. Following the completion of the transaction, the chief executive officer now directly owns 200,942 shares of the company's stock, valued at $492,307.90. Learn More on Douglas Love's trading history.

Who are Annexon's active insiders?

Annexon's insider roster includes Sanjay Keswani (EVP), Jennifer Lew (CFO), Douglas Love (CEO), and Ted Yednock (EVP). Learn More on Annexon's active insiders.

Are insiders buying or selling shares of Annexon?

During the last twelve months, Annexon insiders bought shares 2 times. They purchased a total of 2,753,988 shares worth more than $10,062,313.92. During the last twelve months, insiders at the sold shares 2 times. They sold a total of 3,243 shares worth more than $20,448.32. The most recent insider tranaction occured on May, 25th when Major Shareholder Bain Capital Life Sciences Inv bought 300,000 shares worth more than $639,000.00. Insiders at Annexon own 19.1% of the company. Learn More about insider trades at Annexon.

Information on this page was last updated on 5/25/2023.

Douglas Love Insider Trading History at Annexon

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/14/2022Buy60,000$2.45$147,000.00200,942View SEC Filing Icon  
9/16/2021Sell7,500$22.05$165,375.00View SEC Filing Icon  
6/7/2021Sell3,750$22.31$83,662.503,750View SEC Filing Icon  
4/1/2021Sell500$28.08$14,040.007,102View SEC Filing Icon  
3/29/2021Sell3,750$25.42$95,325.003,750View SEC Filing Icon  
See Full Table

Douglas Love Buying and Selling Activity at Annexon

This chart shows Douglas Love's buying and selling at Annexon by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Annexon Company Overview

Annexon logo
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, a monoclonal antibody, which is in Phase II/III clinical trials to treat patients with guillain- barré syndrome; Phase II trial in patients with warm autoimmune hemolytic anemia; and Phase II clinical trial for Huntington's disease and amyotrophic lateral sclerosis. The company is also developing ANX009 that is in Phase Ib trial in patients with lupus nephritis; and ANX007, which is in Phase II clinical trials to treat patients with geographic atrophy. In addition, it develops ANX105, an investigational monoclonal antibody targeting neurodegenerative indications; and ANX1502, an investigational oral small molecule for the treatment of certain autoimmune indications. The company was incorporated in 2011 and is headquartered in Brisbane, California.
Read More

Today's Range

Now: $3.22
Low: $3.01
High: $3.25

50 Day Range

MA: $4.70
Low: $2.10
High: $6.37

2 Week Range

Now: $3.22
Low: $2.07
High: $7.65


699,337 shs

Average Volume

1,582,332 shs

Market Capitalization

$170.92 million

P/E Ratio


Dividend Yield